Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial
Eve T. Rodler, Priyanka Sharma, William E. Barlow, Julie R. Gralow, Shannon L. Puhalla, Carey K. Anders, Lori J. Goldstein, Debu Tripathy, Ursa Brown‐Glaberman, Thu-Tam Huynh, Christopher S Szyarto, Andrew K. Godwin, Harsh B. Pathak, Elizabeth M. Swisher, Marc R. Radke, Kirsten M. Timms, Danika L. Lew, Jieling Miao, Lajos Pusztai, Daniel F. Hayes, Gabriel N. Hortobágyi
Topics & Concepts
Breast cancerVeliparibBRCA mutationPARP inhibitorMedicineMetastatic breast cancerInternal medicineOncologyTriple-negative breast cancerPlaceboCancerChemotherapyPathologyBiologyPoly ADP ribose polymeraseGeneticsPolymeraseAlternative medicineGenePARP inhibition in cancer therapyBRCA gene mutations in cancerBreast Cancer Treatment Studies